Alliance For Clinical Trials In Oncology

This study tests whether giving chemotherapy both before and after surgery (perioperative) works better than giving it only after surgery (adjuvant) for people with pancreatic cancer that can be surgically removed. About 358 participants will receive a combination of standard che…

This study tests whether genetic testing can help doctors choose the right drug for people whose cancer has spread to the brain. About 50 adults with solid tumors that have certain gene changes (like NTRK, ROS1, or KRAS) will receive a targeted pill. The goal is to see if these d…

This study compares two treatments for people with a specific type of brain tumor (anaplastic or low-grade glioma with 1p/19q co-deletion). One group gets radiation plus the drug temozolomide, the other gets radiation plus a different chemo combo called PCV. The goal is to see wh…

This phase 3 study tests whether adding tucatinib to the targeted therapy T-DM1 can better prevent HER2-positive breast cancer from coming back in high-risk patients. About 1,056 participants who still have cancer after initial treatment will receive either T-DM1 alone or T-DM1 p…

This study tests whether adding rucaparib to standard enzalutamide helps men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 61 men will receive either the combination or enzalutamide alone. The goal is to see if the combo delays can…

This study tests whether adding two targeted drugs (encorafenib and cetuximab) after standard surgery and chemotherapy can lower the chance of cancer coming back in people with a specific genetic type of stage II/III colon cancer (BRAF V600E). Participants either receive the drug…

This study is for people with a rare and aggressive type of lymphoma (peripheral T-cell lymphoma) that hasn't been treated yet. It compares standard chemotherapy alone to chemotherapy plus either duvelisib or CC-486, two drugs that may help stop cancer growth. The goal is to see …

This study compares low-dose tamoxifen to standard hormone therapy (like aromatase inhibitors) in postmenopausal women with early-stage, hormone-positive, HER2-negative breast cancer. The goal is to see if the lower dose works just as well to prevent cancer from coming back, with…

This study tests a chemotherapy combination (gemcitabine and cisplatin) in people with muscle-invasive bladder cancer. The goal is to see if those with certain gene changes can avoid bladder removal and keep their bladder cancer-free. About 237 participants will receive the drugs…

This phase 3 study tests whether giving a combination of two hormone-blocking drugs (fulvestrant and anastrozole) or fulvestrant alone before surgery works better than the standard anastrozole alone for shrinking estrogen receptor-positive breast cancer in postmenopausal women. A…

This study looks at whether men with metastatic prostate cancer that has responded extremely well to hormone therapy can safely take a break from treatment. The goal is to see if pausing therapy allows their testosterone levels to return to normal, potentially improving quality o…

This study tests a technique called axillary reverse mapping (ARM) to see if it can prevent lymphedema—painful arm swelling—after breast cancer surgery. About 534 women with early-stage breast cancer will be followed for 3 years. The goal is to preserve the arm's lymph drainage d…

This study tests enzalutamide, a drug already approved for prostate cancer, in 46 people with advanced salivary gland cancer that has androgen receptors. The goal is to see if the drug can shrink tumors by at least 30% in 1 out of 5 patients. Researchers are also tracking how lon…

This study compares a three-drug chemotherapy combination (nab-paclitaxel, gemcitabine, plus cisplatin) against the standard two-drug combination (nab-paclitaxel plus gemcitabine) for people with metastatic pancreatic cancer that has spread to other parts of the body. Participant…

This study tests whether adding high-dose vitamin D3 to standard chemotherapy and a targeted drug (bevacizumab) can help people with metastatic colorectal cancer live longer without their disease getting worse. About 455 patients who have not had prior treatment for advanced dise…

This study tests whether a three-drug chemotherapy combination (FOLFIRINOX) works better than standard two-drug combinations (FOLFOX or CAPOX) after radiation for stage II-III rectal cancer. The goal is to see if more patients can achieve a complete response, potentially avoiding…

This study compares a new treatment that combines a targeted drug (inotuzumab) with standard chemotherapy against chemotherapy alone for older adults with B-cell acute lymphoblastic leukemia or lymphoma. The targeted drug works like a smart bomb, attaching to cancer cells and del…

This study tested whether adding everolimus to the standard drug sorafenib helps people with a rare, advanced thyroid cancer that no longer responds to radioactive iodine. The trial included 35 adults with measurable tumors. Researchers measured how long the cancer stayed under c…

This study tests whether adding the immunotherapy drug cemiplimab to the targeted therapy palbociclib works better than palbociclib alone for people with advanced dedifferentiated liposarcoma, a rare and aggressive cancer. About 77 adults with cancer that has spread or cannot be …

This study looks at two ways to give radiation after surgery for cancer that has spread to the brain. One method uses a single, strong dose of radiation, while the other uses several smaller doses over time. The goal is to see which approach better prevents the tumor from coming …

This study tests whether adding cetuximab to avelumab helps people with advanced skin squamous cell cancer live longer without their cancer growing. About 60 adults with cancer that has spread will receive either avelumab alone or avelumab plus cetuximab. The goal is to see if th…

This study tests whether a shorter course of radiation (hypofractionated) after mastectomy works as well as standard radiation to prevent breast cancer from coming back. About 900 women with stage II to IIIA breast cancer who had a mastectomy and reconstruction are taking part. T…

This study looks at two different chemotherapy treatments for people newly diagnosed with primary CNS B-cell lymphoma, a rare type of brain cancer. One group gets high-dose chemotherapy followed by a stem cell transplant, while the other gets standard chemotherapy alone. The goal…

This study looks at whether people with advanced bladder cancer can stop taking immunotherapy drugs after about a year without hurting their chances of survival. The goal is to see if stopping early leads to fewer side effects, better quality of life, and lower costs, while still…

This study tests whether metformin, a common diabetes drug, can prevent breast cancer in women at high risk. Participants take metformin or a placebo for 12 months to see if it reduces abnormal cell growth in breast tissue. The goal is to find a safe, affordable way to lower canc…

This study tests whether duloxetine, a drug typically used for depression and pain, can prevent the nerve damage (pain, tingling, numbness) caused by the chemotherapy drug oxaliplatin in people with stage II or III colorectal cancer. About 220 participants will receive either dul…

This study tests whether adding text message reminders and/or telephone counseling helps breast cancer patients take their daily hormone therapy pills more consistently. About 1,167 women with early-stage hormone receptor-positive breast cancer will be followed for up to two year…

This study compares two drugs, olanzapine and megestrol acetate, to see which works better for improving appetite and preventing weight loss in people with advanced cancer. About 227 patients will take one of the two medications for four weeks. The goal is to find a more effectiv…

This study looks at whether a pre-surgical toolkit (OPTI-Surg) can improve recovery in older adults with cancer who are having major surgery. The toolkit provides recommendations before surgery to help patients regain physical function faster. About 325 participants will be follo…

This trial is testing whether a substance called GM1 can prevent or reduce nerve damage caused by paclitaxel chemotherapy. The study involves about 100 people with metastatic breast cancer who are receiving paclitaxel treatment. Researchers want to see if giving GM1 alongside che…

This study tests a decision aid designed to help people with early-stage breast cancer (stages 0 to III) feel more confident and involved when choosing their surgery. The goal is to see if the tool works, especially for patients with lower income or education. Researchers will me…